ArticleWorld journal of surgical oncology2025
SUZ12 knockdown restrains the proliferation, migration, and invasion of oral tongue squamous cell carcinoma through inhibiting DNMT1-mediated ZNF582 promoter methylation.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSuppressor of zest 12 (SUZ12) upregulation is related to cervical node metastasis in oral tongue squamous cell carcinoma (OTSCC). This study explored the roles and mechanism of SUZ12 in OTSCC progression.
methodsSUZ12 protein levels in OTSCC tissues and cell lines were determined using immunohistochemistry assay and Western blot analysis. SUZ12 was overexpressed or silenced through transfection of Overexpression plasmids or small interfering RNA targeting SUZ12 were transfected into CAL27 and SCC9 cells to achieve SUZ12 overexpression or knockdown. Subsequently, cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin and Vimentin) were determined. Zinc finger protein 582 (ZNF582) promoter methylation was detected using the methylation-specific PCR assay. Then, the effects of ZNF582 on CAL27 cell behaviors were also evaluated using gain/loss function experiments. Moreover, rescue experiments were conducted to investigate the role of the SUZ12/ZNF582 axis in regulating CAL27 cell progression. Additionally, SUZ12-silenced CAL27 cells were subcutaneously injected into the posterior flank of mice, followed by tumor growth detection within a 28 day period.
resultsSUZ12 protein was significantly upregulated in OTSCC tissues and cell lines. SUZ12 overexpression augmented proliferation, migration, invasion and EMT in both CAL27 and SCC9 cells, while SUZ12 knockdown showed the opposite results. SUZ12 inhibited ZNF582 expression by promoting DNA methyltransferase 1 (DNMT1)-mediated ZNF582 promoter methylation. Moreover, ZNF582 knockdown promoted OTSCC cell proliferation, migration, invasion and EMT, while ZNF582 overexpression led to the opposite results. Rescue experiments demonstrated that ZNF582 knockdown abrogated SUZ12 knockdown-mediated inhibition of CAL27 cell malignant progression. Besides, SUZ12 knockdown suppressed xenograft tumor growth of OTSCC in nude mice.
conclusionSUZ12 knockdown inhibits the proliferation, migration, invasion and EMT in OTSCC cells by inhibiting DNMT1-mediated ZNF582 promoter methylation, thereby suppressing tumor growth in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.